Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Beijing Biostar Pharmaceuticals Co., Ltd.
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07021261CT.gov Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients | — | Not Yet Recruiting | — | — | — |
NCT06102824CT.gov Organoid-based Functional Precision Therapy for Advanced Breast Cancer | — | Recruiting | — | — | — |
NCT06510465CT.gov Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA) | — | Not Yet Recruiting | — | — | — |
NCT06598046CT.gov A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined with Capecitabine in the Treatment of Active Brain Metastasis of TNBC | — | Recruiting | — | — | — |
NCT06458413CT.gov Utidelone Capsule Plus Capecitabine (CAP) for Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT05983094CT.gov Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT05673629CT.gov Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer | — | Unknown | — | — | — |
NCT05430399CT.gov Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT05403333CT.gov Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT05357417CT.gov Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases | — | Unknown | — | — | — |
Show 2 more trialsShow fewer
NCT05172518CT.gov Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT05052437CT.gov PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Utidelone (this asset) | Beijing Biostar Pharmaceuticals Co., Ltd. | P3 | B · 58 |
| Darolutamide | Vandana Abramson | P2 | BBB |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Palbociclib | Hoffmann-La Roche | P4 | BB |
| Trastuzumab Duocarmazine | Byondis B.V. | P3 | BB |
| Goserelin | TerSera Therapeutics LLC | P4 | BB |
| Ribociclib | National Cancer Institute (NCI) | P4 | BB |
| Oxaliplatin | Beijing Biostar Pharmaceuticals Co., Ltd. | P4 | BB |
| Eribulin Monomethanesulfonate | Henan Cancer Hospital | P4 | BB |
+42 more in the Breast Cancer cohort
Other indications for Utidelone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P3 | B · 62 |
| Triple-Negative Breast Carcinoma | — | P3 | B · 62 |
| Breast Neoplasm | — | P3 | B · 56 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Utidelone in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/utidelone-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →